Summary of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, € in Thousands							1 Months Ended	3 Months Ended									12 Months Ended
	Dec. 28, 2014 USD ($)	Sep. 03, 2014 USD ($)	Jan. 30, 2014 USD ($)	Sep. 04, 2013 USD ($)	Jan. 22, 2013 USD ($)	Apr. 06, 2007 shares	Sep. 30, 2014 USD ($)	Dec. 31, 2016 USD ($) Investment $ / shares shares	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2016 USD ($) Investment Segment $ / shares shares	Dec. 31, 2016 EUR (€) Segment shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2016 EUR (€) Investment shares	May 24, 2016 USD ($)	Apr. 01, 2016 USD ($)	Jun. 02, 2014 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares purchased through issuance of warrants | shares						150,000
Warrant term						7 years
Revenue recognized																	$ 2,115,000
Non-refundable up-front payment																	2,000,000
Payment to be received upon signing of agreement																	125,675
Revenue recognized under revenue recognition, up front payment																$ 2,000,000
Royalty and other revenue								$ 100,000									$ 100,000			$ 3,117,000
Long-term marketable securities, minimum original maturity term																	1 year	1 year
Marketable securities, average remaining contractual maturity period																	3 years 10 months 24 days	3 years 10 months 24 days
Long-term marketable securities								$ 0				$ 1,633,000					$ 0		$ 1,633,000
Number of debt securities in unrealized loss positions | Investment								15									15				15
Debt securities in unrealized loss positions, total unrealized loss								$ 7,000									$ 7,000
Debt securities in unrealized loss positions, total fair market value								9,758,000									9,758,000
Credit risk								0									0
Gain (loss) on investments																	0		0	0
Fair value of other assets								0									0
Fair value of other liabilities								0									0
Increase to milestone payment								(75,000)	$ 675,000	$ 637,000	$ 2,005,000	1,969,000	$ 233,000	$ 768,000	$ 1,112,000		3,242,000		4,083,000	$ 2,072,000
Payment of contingent considerations																	798,000		99,000
Reserves for excess and obsolete inventory								$ 435,000				$ 343,000					$ 435,000		$ 343,000
Stock options, outstanding | shares								882,748				1,054,584					882,748		1,054,584		882,748
Stock options, weighted average exercise price | $ / shares								$ 16.88				$ 12.28					$ 16.88		$ 12.28
Common stock excluded from calculation of diluted earnings per share | shares																	381,686	381,686	196,209	307,475
Number of operating segment | Segment																	1	1
Long Lived Assets								$ 104,760,000				$ 42,985,000					$ 104,760,000		$ 42,985,000
Goodwill impairment																	0		0	$ 0
Amortization expense																	$ 2,052,000		1,600,000	$ 1,425,000
2.125% Convertible Senior Notes due 2021
Summary Of Significant Accounting Policies [Line Items]
Principal amount																						$ 115,000,000
Notes, due date																	Jun. 01, 2021	Jun. 01, 2021
Notes, frequency of periodic payment																	Semi-annually	Semi-annually
Notes, date of first required payment																	Dec. 01, 2016	Dec. 01, 2016
Total convertible senior notes								95,272,000									$ 95,272,000
Fair value of convertible senior notes								135,600,000									135,600,000
Singapore
Summary Of Significant Accounting Policies [Line Items]
Long Lived Assets								0				$ 0					$ 0		0
Minimum
Summary Of Significant Accounting Policies [Line Items]
Short-term marketable securities, minimum original maturity term																	90 days	90 days
Licensing Agreements | Scripps Research Institute
Summary Of Significant Accounting Policies [Line Items]
License Agreement, initial license fee																	$ 300,000
Total future milestone payments																	$ 4,300,000
Common stock, shares issued | shares																	87,464	87,464
Common stock, shares issued value																	$ 300,000
Common stock, shares purchased through issuance of warrants | shares																				150,000
Warrant term																				7 years
Technology Transfer
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized																$ 0
Estimated selling price								300,000									300,000
Consideration allocated to transaction								11,000									11,000
Royalty and other revenue							$ 125,675
Non-software License Arrangement | Pfizer Incorporation
Summary Of Significant Accounting Policies [Line Items]
Upfront payment received under license agreement					$ 5,000,000
Milestone Payment	$ 1,000,000			$ 1,000,000
Atoll GmbH
Summary Of Significant Accounting Policies [Line Items]
Contingent consideration fair value																							$ 952,000
Atoll GmbH | Significant unobservable inputs (Level 3)
Summary Of Significant Accounting Policies [Line Items]
Contingent consideration fair value								1,052,000									1,052,000				€ 1,000
Atoll GmbH | Milestone Payments | Significant unobservable inputs (Level 3)
Summary Of Significant Accounting Policies [Line Items]
Increase to milestone payment																	182,000	€ 164
Contingent consideration fair value								928,000									928,000				€ 836
Refine Technology, LLC
Summary Of Significant Accounting Policies [Line Items]
Contingent consideration fair value								$ 952,000									952,000			$ 1,370,000				$ 1,370,000
Refine Technology, LLC | Milestone Payments
Summary Of Significant Accounting Policies [Line Items]
Increase to milestone payment																	3,048,000
Payment of contingent considerations																	4,350,000		$ 1,000,000
Contingent consideration fair value																								$ 1,370,000
Refine Technology, LLC | Milestone Payments | Significant unobservable inputs (Level 3)
Summary Of Significant Accounting Policies [Line Items]
Increase to milestone payment																	3,048,000
Bio Flash
Summary Of Significant Accounting Policies [Line Items]
Payment of contingent considerations																	500,000
Bio Flash | Minimum
Summary Of Significant Accounting Policies [Line Items]
Royalty payment																	130,000,000
Bio Flash | Selling, general and administrative
Summary Of Significant Accounting Policies [Line Items]
Payment of contingent considerations																	199,000
Bio Flash | Contingent Consideration
Summary Of Significant Accounting Policies [Line Items]
Payment of contingent considerations																	$ 301,000
Option To Purchase Common Stock
Summary Of Significant Accounting Policies [Line Items]
Stock options, outstanding | shares								1,236,586				1,240,935					1,236,586		1,240,935	1,225,117	1,236,586
Stock options, weighted average exercise price | $ / shares								$ 12.05				$ 10.44					$ 12.05		$ 10.44	$ 8.31
Employee Stock Option | Awards Granted to Non-Executive Level Employees
Summary Of Significant Accounting Policies [Line Items]
Estimated forfeiture rates								8.00%									8.00%			8.00%	8.00%
Employee Stock Option | Awards Granted to Executive Level Employees
Summary Of Significant Accounting Policies [Line Items]
Estimated forfeiture rates								3.00%									3.00%			3.00%	3.00%
Non-Employee Directors
Summary Of Significant Accounting Policies [Line Items]
Estimated forfeiture rates																				0.00%
Clinical Development
Summary Of Significant Accounting Policies [Line Items]
Milestone Payment																	$ 60,000,000
Potential milestone payments to be received								$ 60,000,000									$ 60,000,000
Royalty term																	10 years	10 years
Initial Commercial Sales
Summary Of Significant Accounting Policies [Line Items]
Potential milestone payments to be received								$ 100,000,000									$ 100,000,000
BioMarin Pharmaceutical, Inc. | Asset Purchase Agreement
Summary Of Significant Accounting Policies [Line Items]
Upfront payment received under license agreement			$ 2,000,000
Potential milestone payments to be received																				$ 160,000,000
Provision for refund																				0
Revenue recognized																				$ 2,100,000
BioMarin Pharmaceutical, Inc. | Clinical Development | Asset Purchase Agreement
Summary Of Significant Accounting Policies [Line Items]
Percentage relate to clinical development from Milestone payment																				37.00%
BioMarin Pharmaceutical, Inc. | Initial Commercial Sales | Asset Purchase Agreement
Summary Of Significant Accounting Policies [Line Items]
Percentage relate to clinical development from Milestone payment																				63.00%
BioMarin Pharmaceutical, Inc. | Technology Transfer Payments | Asset Purchase Agreement
Summary Of Significant Accounting Policies [Line Items]
Milestone Payment		$ 125,675